Pantothenate kinase-associated neurodegeneration.

Neurosciences (Riyadh)

Division of Neurology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia. E-mail:

Published: April 2017

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726824PMC
http://dx.doi.org/10.17712/nsj.2017.2.20170197DOI Listing

Publication Analysis

Top Keywords

pantothenate kinase-associated
4
kinase-associated neurodegeneration
4
pantothenate
1
neurodegeneration
1

Similar Publications

Pathology and treatment methods in pantothenate kinase-associated neurodegeneration.

Postep Psychiatr Neurol

September 2024

Independent Public Health Care Institution named after doctor Kazimierz Hołoga, Nowy Tomyśl, Poland.

Purpose: The purpose of this review is to present current scientific reports on the pathophysiology, diagnosis and treatment of pantothenate kinase-associated neurodegeneration (PKAN).

Views: The condition is caused by a mutation in the PANK2 gene, which results in iron accumulation in the brain and changes in the functioning of biochemical pathways dependent on coenzyme A. There are two clinical types of PKAN, which differ in the time of onset of symptoms and speed of disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • * The diagnosis of PKAN relies on clinical observations, a specific brain MRI finding called the "eye of the tiger," and genetic testing for mutations in the pantothenate kinase 2 (PANK2) gene, which plays a crucial role in coenzyme A (CoA) production.
  • * Research shows that combining multitarget supplements (like pantothenate, pantethine, omega-3, and vitamin E) with standard
View Article and Find Full Text PDF

Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive hereditary neurodegenerative disorder, usually caused by mutations in the pantothenate kinase 2 (PANK2) gene. We report a young female patient with atypical PKAN, harboring a novel heterozygous PANK2 mutation, diagnosed through clinical imaging and genetic analysis. The patient presented with dystonia and motor dysfunction after onset, but early brain MRI showed normal findings.

View Article and Find Full Text PDF

Patient Selection for Deep Brain Stimulation for Pantothenate Kinase-Associated Neurodegeneration.

Tremor Other Hyperkinet Mov (N Y)

October 2024

Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.

Clinical Vignette: A 23-year-old woman with pantothenate kinase-associated neurodegeneration (PKAN) presented with medication-refractory generalized dystonia and an associated gait impairment.

Clinical Dilemma: Bilateral globus pallidus internus (GPi) deep brain stimulation (DBS) can be an effective treatment for dystonia. However, outcomes for PKAN DBS have been variable and there are no standardized criteria for patient selection.

View Article and Find Full Text PDF
Article Synopsis
  • Mutations in several genes, like PANK2 and PLA2G6, are linked to different subtypes of the inherited disease Neurodegeneration with Brain Iron Accumulation (NBIA), with four main subtypes accounting for the majority of cases.
  • Recent findings suggest additional mutations affecting iron and lipid metabolism may also contribute to the disease's development.
  • A study on fibroblasts from patients with C19orf12 mutations found abnormalities that correlated with disease severity, indicating these cellular changes could be important in understanding the pathomechanism of NBIA.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!